CRC Research Update — August 27, 2026
Today's colorectal cancer research highlights
Archive
A collection of 715 issues
Latest
Oncogenic KRAS and BRAF Drive Lactate-Mediated Immune Suppression in Microsatellite-Stable CRC
Skip to content
The CRC Digest
◇ RESEARCH
Oncogenic KRAS and BRAF Drive Lactate-Mediated Immune Suppression in Microsatellite-Stable CRC
A mechanistic review describes how KRAS and BRAF mutations drive aerobic glycolysis and lactate accumulation, which suppresses T-cell function and contributes to immunotherapy resistance in MSS tumors. (Int J Mol Sci)
This
Kazakhstan Study Links KRAS Mutation Detection Methods to Survival in Stage II-IV CRC
Skip to content
The CRC Digest
◇ RESEARCH
Kazakhstan Study Links KRAS Mutation Detection Methods to Survival in Stage II-IV CRC
A 332-patient cohort study compared KRAS variant detection by real-time and digital PCR in tumor tissue and plasma, examining associations with overall survival across stage II-IV disease. (Genes)
This content
Lynch Syndrome Screening Performance Assessed in Early-Onset CRC Cohort
Skip to content
The CRC Digest
◇ RESEARCH
Lynch Syndrome Screening Performance Assessed in Early-Onset CRC Cohort
The Padua study specifically evaluated mismatch repair testing and Lynch syndrome detection in early-onset CRC patients as part of a universal screening approach. (Cancers)
This content is informational only and does not constitute medical
Comprehensive Review Examines Mechanisms and Management of Irinotecan-Induced Delayed Diarrhea
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Comprehensive Review Examines Mechanisms and Management of Irinotecan-Induced Delayed Diarrhea
A systematic review details how irinotecan's active metabolite SN38 affects the intestinal microenvironment—including flora disruption, immune dysregulation, and barrier impairment—and explores current therapeutic approaches to manage this
Circulating Tumor DNA Shows Promise for Guiding Adjuvant Therapy After Curative Surgery
Skip to content
The CRC Digest
◇ RESEARCH
Circulating Tumor DNA Shows Promise for Guiding Adjuvant Therapy After Curative Surgery
A review examines how circulating tumor DNA (ctDNA) offers a dynamic readout of molecular residual disease in the postoperative period, potentially guiding adjuvant treatment decision-making in stage II (15-20% recurrence) and
Universal Tumor Screening Evaluated for Lynch Syndrome Detection in 1,022 Consecutive CRC Cases
Skip to content
The CRC Digest
▪ SCREENING
Universal Tumor Screening Evaluated for Lynch Syndrome Detection in 1,022 Consecutive CRC Cases
A University Hospital of Padua study assessed mismatch repair deficiency distribution and Lynch syndrome detection rates across clinical subgroups using immunohistochemistry-based universal tumor screening in consecutive surgical patients. (Cancers)
Genomic Analysis Reveals Distinct Mutation Patterns in Early-Onset vs. Average-Onset Metastatic CRC
Skip to content
The CRC Digest
◇ RESEARCH
Genomic Analysis Reveals Distinct Mutation Patterns in Early-Onset vs. Average-Onset Metastatic CRC
A real-world next-generation sequencing study of 1,892 metastatic CRC patients found genomic differences between 376 early-onset cases (diagnosed before age 50) and 1,516 average-onset cases, potentially informing personalized treatment
MD Anderson explains DNA mismatch repair status for patients
Skip to content
The CRC Digest
MD Anderson explains DNA mismatch repair status for patients
An educational resource from MD Anderson helps patients understand mismatch repair deficiency and proficiency, key biomarkers that guide immunotherapy decisions. (UT MD Anderson Cancer Center)
This content is informational only and does not constitute medical
Kazakhstani pilot study profiles KRAS and BRAF mutations using NGS and ddPCR
Skip to content
The CRC Digest
Kazakhstani pilot study profiles KRAS and BRAF mutations using NGS and ddPCR
Researchers used targeted next-generation sequencing and droplet digital PCR to characterize KRAS and BRAF mutations in metastatic colorectal cancer patients from Kazakhstan, where molecular epidemiological data remain limited. (Frontiers in Medicine)
This